SERUM B-CELL MATURATION ANTIGEN IS A BIOMARKER FOR PATIENTS WITH B-CELL DISORDERS
(Abstract release date: 05/19/16)
EHA Library. Berenson J. 06/09/16; 132839; E1290
Mr. James Berenson
Contributions
Contributions
Abstract
Abstract: E1290
Type: Eposter Presentation
Background
Serum B-cell maturation antigen (sBCMA) is a tumor necrosis factor receptor family member that is expressed on normal and malignant B-cells including plasma cells.
Aims
We determined sBCMA levels in large cohorts of patients (pts) with multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and Waldenström’s macroglobulinemia (WM) and immune deficiency (ID) including common variable immune deficiency (CVID) and X-linked agammaglobulinemia (XLA).
Methods
Serum was obtained on healthy individuals and pts with B-cell disorders following informed consent. Enzyme-linked immunosorbent assay (ELISA) was used to determine sBCMA levels (R&D Systems, Minneapolis, MN). Kaplan-Meier survival analysis and log-rank comparison tests were used to determine the association between sBCMA levels and time to first treatment (TTFT), overall survival (OS) and progression-free survival (PFS). Similarly, sBCMA levels were correlated with bone marrow (BM) and PET scan findings for non-secretory disease (NSD) MM pts. Proportional Hazard Regression Analysis and a multivariate analysis were utilized to determine the predictive ability of sBCMA on OS and other prognostic factors including: age, serum creatinine, serum hemoglobin, and ISS staging. One-way univariate analysis of variance was performed to study the relationship of sBCMA with bone disease status, based on presence of osteopenia, osteolytic lesions and fractures as well as the clinical status. All of the statistical analysis was performed using JMP Pro for Windows by SAS and P values <0.05 are reported as statistically significant.
Results
Compared to healthy donors (n=43), pts with untreated active MM (n=44) showed increased levels of sBCMA (P<0.0001). sBCMA levels correlated with changes in BM plasma cell involvement (Pearson r=0.609; p<0.0001) and current clinical status (n=164, P-values: 0.0045 CR vs PR; < 0.0001 CR vs NR) for MM pts. Those with other untreated B-cell malignancies showed increased levels (CLL: n=94, WM: n=29, both P<0.0001). sBCMA correlated with changes in M-protein levels for MM and WM pts and changes in clinical status among both MM and CLL pts. Furthermore, sBCMA also correlated with PET scan and BM findings among MM pts with NSD. Kaplan-Meier analysis demonstrated that sBCMA levels predict PFS (P=0.0004) and OS (P=0.0043) among pts with MM (n=242). sBCMA levels correlated with depth of response (P-values: 0.05 CR vs PR, 0.03 CR vs SD, and 0.004 CR vs PD). Among CLL pts (n=171), sBCMA levels predicted TTFT (P<0.0001) and OS (P=0.02), and correlated with WBC count, serum ß2-microglobulin level, IgVH mutational status, ZAP-70 scores, and chromosome 13 deletion. Additionally, sBCMA did not correlate with renal function or presence of the bone disease or other prognostic factors and maintained independent significance when tested in cohorts of MM (n=188, Pairwise R=0.18) or CLL (n=155, Pairwise R=0.001) pts. Compared to healthy donors (n=104), pts with an ID showed lower levels of sBCMA (CVID: n=46; XLA: n=8; both P<0.0001). Among pts with CVID, sBCMA correlated with complications from the disease (P=0.01).
Conclusion
We have identified sBCMA as a novel independent diagnostic and prognostic biomarker that can monitor and predict outcomes for pts with MM, CLL and WM which show elevated levels whereas those with ID including CVID and XLA show decreased levels. Levels of this marker among pts with B-cell malignancies also correlate with clinical status, predict TTFT, PFS and OS, and provide MM pts with NSD a way to follow their disease course.
Session topic: E-poster
Keyword(s): Chronic lymphocytic leukemia, Immune deficiency, Multiple myeloma, Waldenstrom's macroglobulinemia
Type: Eposter Presentation
Background
Serum B-cell maturation antigen (sBCMA) is a tumor necrosis factor receptor family member that is expressed on normal and malignant B-cells including plasma cells.
Aims
We determined sBCMA levels in large cohorts of patients (pts) with multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and Waldenström’s macroglobulinemia (WM) and immune deficiency (ID) including common variable immune deficiency (CVID) and X-linked agammaglobulinemia (XLA).
Methods
Serum was obtained on healthy individuals and pts with B-cell disorders following informed consent. Enzyme-linked immunosorbent assay (ELISA) was used to determine sBCMA levels (R&D Systems, Minneapolis, MN). Kaplan-Meier survival analysis and log-rank comparison tests were used to determine the association between sBCMA levels and time to first treatment (TTFT), overall survival (OS) and progression-free survival (PFS). Similarly, sBCMA levels were correlated with bone marrow (BM) and PET scan findings for non-secretory disease (NSD) MM pts. Proportional Hazard Regression Analysis and a multivariate analysis were utilized to determine the predictive ability of sBCMA on OS and other prognostic factors including: age, serum creatinine, serum hemoglobin, and ISS staging. One-way univariate analysis of variance was performed to study the relationship of sBCMA with bone disease status, based on presence of osteopenia, osteolytic lesions and fractures as well as the clinical status. All of the statistical analysis was performed using JMP Pro for Windows by SAS and P values <0.05 are reported as statistically significant.
Results
Compared to healthy donors (n=43), pts with untreated active MM (n=44) showed increased levels of sBCMA (P<0.0001). sBCMA levels correlated with changes in BM plasma cell involvement (Pearson r=0.609; p<0.0001) and current clinical status (n=164, P-values: 0.0045 CR vs PR; < 0.0001 CR vs NR) for MM pts. Those with other untreated B-cell malignancies showed increased levels (CLL: n=94, WM: n=29, both P<0.0001). sBCMA correlated with changes in M-protein levels for MM and WM pts and changes in clinical status among both MM and CLL pts. Furthermore, sBCMA also correlated with PET scan and BM findings among MM pts with NSD. Kaplan-Meier analysis demonstrated that sBCMA levels predict PFS (P=0.0004) and OS (P=0.0043) among pts with MM (n=242). sBCMA levels correlated with depth of response (P-values: 0.05 CR vs PR, 0.03 CR vs SD, and 0.004 CR vs PD). Among CLL pts (n=171), sBCMA levels predicted TTFT (P<0.0001) and OS (P=0.02), and correlated with WBC count, serum ß2-microglobulin level, IgVH mutational status, ZAP-70 scores, and chromosome 13 deletion. Additionally, sBCMA did not correlate with renal function or presence of the bone disease or other prognostic factors and maintained independent significance when tested in cohorts of MM (n=188, Pairwise R=0.18) or CLL (n=155, Pairwise R=0.001) pts. Compared to healthy donors (n=104), pts with an ID showed lower levels of sBCMA (CVID: n=46; XLA: n=8; both P<0.0001). Among pts with CVID, sBCMA correlated with complications from the disease (P=0.01).
Conclusion
We have identified sBCMA as a novel independent diagnostic and prognostic biomarker that can monitor and predict outcomes for pts with MM, CLL and WM which show elevated levels whereas those with ID including CVID and XLA show decreased levels. Levels of this marker among pts with B-cell malignancies also correlate with clinical status, predict TTFT, PFS and OS, and provide MM pts with NSD a way to follow their disease course.
Session topic: E-poster
Keyword(s): Chronic lymphocytic leukemia, Immune deficiency, Multiple myeloma, Waldenstrom's macroglobulinemia
Abstract: E1290
Type: Eposter Presentation
Background
Serum B-cell maturation antigen (sBCMA) is a tumor necrosis factor receptor family member that is expressed on normal and malignant B-cells including plasma cells.
Aims
We determined sBCMA levels in large cohorts of patients (pts) with multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and Waldenström’s macroglobulinemia (WM) and immune deficiency (ID) including common variable immune deficiency (CVID) and X-linked agammaglobulinemia (XLA).
Methods
Serum was obtained on healthy individuals and pts with B-cell disorders following informed consent. Enzyme-linked immunosorbent assay (ELISA) was used to determine sBCMA levels (R&D Systems, Minneapolis, MN). Kaplan-Meier survival analysis and log-rank comparison tests were used to determine the association between sBCMA levels and time to first treatment (TTFT), overall survival (OS) and progression-free survival (PFS). Similarly, sBCMA levels were correlated with bone marrow (BM) and PET scan findings for non-secretory disease (NSD) MM pts. Proportional Hazard Regression Analysis and a multivariate analysis were utilized to determine the predictive ability of sBCMA on OS and other prognostic factors including: age, serum creatinine, serum hemoglobin, and ISS staging. One-way univariate analysis of variance was performed to study the relationship of sBCMA with bone disease status, based on presence of osteopenia, osteolytic lesions and fractures as well as the clinical status. All of the statistical analysis was performed using JMP Pro for Windows by SAS and P values <0.05 are reported as statistically significant.
Results
Compared to healthy donors (n=43), pts with untreated active MM (n=44) showed increased levels of sBCMA (P<0.0001). sBCMA levels correlated with changes in BM plasma cell involvement (Pearson r=0.609; p<0.0001) and current clinical status (n=164, P-values: 0.0045 CR vs PR; < 0.0001 CR vs NR) for MM pts. Those with other untreated B-cell malignancies showed increased levels (CLL: n=94, WM: n=29, both P<0.0001). sBCMA correlated with changes in M-protein levels for MM and WM pts and changes in clinical status among both MM and CLL pts. Furthermore, sBCMA also correlated with PET scan and BM findings among MM pts with NSD. Kaplan-Meier analysis demonstrated that sBCMA levels predict PFS (P=0.0004) and OS (P=0.0043) among pts with MM (n=242). sBCMA levels correlated with depth of response (P-values: 0.05 CR vs PR, 0.03 CR vs SD, and 0.004 CR vs PD). Among CLL pts (n=171), sBCMA levels predicted TTFT (P<0.0001) and OS (P=0.02), and correlated with WBC count, serum ß2-microglobulin level, IgVH mutational status, ZAP-70 scores, and chromosome 13 deletion. Additionally, sBCMA did not correlate with renal function or presence of the bone disease or other prognostic factors and maintained independent significance when tested in cohorts of MM (n=188, Pairwise R=0.18) or CLL (n=155, Pairwise R=0.001) pts. Compared to healthy donors (n=104), pts with an ID showed lower levels of sBCMA (CVID: n=46; XLA: n=8; both P<0.0001). Among pts with CVID, sBCMA correlated with complications from the disease (P=0.01).
Conclusion
We have identified sBCMA as a novel independent diagnostic and prognostic biomarker that can monitor and predict outcomes for pts with MM, CLL and WM which show elevated levels whereas those with ID including CVID and XLA show decreased levels. Levels of this marker among pts with B-cell malignancies also correlate with clinical status, predict TTFT, PFS and OS, and provide MM pts with NSD a way to follow their disease course.
Session topic: E-poster
Keyword(s): Chronic lymphocytic leukemia, Immune deficiency, Multiple myeloma, Waldenstrom's macroglobulinemia
Type: Eposter Presentation
Background
Serum B-cell maturation antigen (sBCMA) is a tumor necrosis factor receptor family member that is expressed on normal and malignant B-cells including plasma cells.
Aims
We determined sBCMA levels in large cohorts of patients (pts) with multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and Waldenström’s macroglobulinemia (WM) and immune deficiency (ID) including common variable immune deficiency (CVID) and X-linked agammaglobulinemia (XLA).
Methods
Serum was obtained on healthy individuals and pts with B-cell disorders following informed consent. Enzyme-linked immunosorbent assay (ELISA) was used to determine sBCMA levels (R&D Systems, Minneapolis, MN). Kaplan-Meier survival analysis and log-rank comparison tests were used to determine the association between sBCMA levels and time to first treatment (TTFT), overall survival (OS) and progression-free survival (PFS). Similarly, sBCMA levels were correlated with bone marrow (BM) and PET scan findings for non-secretory disease (NSD) MM pts. Proportional Hazard Regression Analysis and a multivariate analysis were utilized to determine the predictive ability of sBCMA on OS and other prognostic factors including: age, serum creatinine, serum hemoglobin, and ISS staging. One-way univariate analysis of variance was performed to study the relationship of sBCMA with bone disease status, based on presence of osteopenia, osteolytic lesions and fractures as well as the clinical status. All of the statistical analysis was performed using JMP Pro for Windows by SAS and P values <0.05 are reported as statistically significant.
Results
Compared to healthy donors (n=43), pts with untreated active MM (n=44) showed increased levels of sBCMA (P<0.0001). sBCMA levels correlated with changes in BM plasma cell involvement (Pearson r=0.609; p<0.0001) and current clinical status (n=164, P-values: 0.0045 CR vs PR; < 0.0001 CR vs NR) for MM pts. Those with other untreated B-cell malignancies showed increased levels (CLL: n=94, WM: n=29, both P<0.0001). sBCMA correlated with changes in M-protein levels for MM and WM pts and changes in clinical status among both MM and CLL pts. Furthermore, sBCMA also correlated with PET scan and BM findings among MM pts with NSD. Kaplan-Meier analysis demonstrated that sBCMA levels predict PFS (P=0.0004) and OS (P=0.0043) among pts with MM (n=242). sBCMA levels correlated with depth of response (P-values: 0.05 CR vs PR, 0.03 CR vs SD, and 0.004 CR vs PD). Among CLL pts (n=171), sBCMA levels predicted TTFT (P<0.0001) and OS (P=0.02), and correlated with WBC count, serum ß2-microglobulin level, IgVH mutational status, ZAP-70 scores, and chromosome 13 deletion. Additionally, sBCMA did not correlate with renal function or presence of the bone disease or other prognostic factors and maintained independent significance when tested in cohorts of MM (n=188, Pairwise R=0.18) or CLL (n=155, Pairwise R=0.001) pts. Compared to healthy donors (n=104), pts with an ID showed lower levels of sBCMA (CVID: n=46; XLA: n=8; both P<0.0001). Among pts with CVID, sBCMA correlated with complications from the disease (P=0.01).
Conclusion
We have identified sBCMA as a novel independent diagnostic and prognostic biomarker that can monitor and predict outcomes for pts with MM, CLL and WM which show elevated levels whereas those with ID including CVID and XLA show decreased levels. Levels of this marker among pts with B-cell malignancies also correlate with clinical status, predict TTFT, PFS and OS, and provide MM pts with NSD a way to follow their disease course.
Session topic: E-poster
Keyword(s): Chronic lymphocytic leukemia, Immune deficiency, Multiple myeloma, Waldenstrom's macroglobulinemia
{{ help_message }}
{{filter}}